2. Search Result
Search Result
Results for "

anesthetized

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

3

Peptides

1

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1323A
    [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA
    1 Publications Verification

    		 Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) TFA can increase blood pressure in anesthetized rats and increases food intake .
    [Leu31,Pro34]-Neuropeptide Y(human,rat,mouse) TFA
  • HY-118470
    Butaxamine hydrochloride

    Butoxamin hydrochloride

    		 Adrenergic Receptor Endocrinology
    Butaxamine (Butoxamin) hydrochloride is a specific β2-adrenergic receptor blocker. Butaxamine hydrochloride inhibits the decreases in urine volume in ethanol-anesthetized, water-diuretic rats .
    Butaxamine hydrochloride
  • HY-105090
    Lerisetron

    		5-HT Receptor Cardiovascular Disease Neurological Disease
    Lerisetron is a potent 5-HT3 antagonists and possess high-affinity binding for the 5-HT3 receptors with pKi value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats .
    Lerisetron
  • HY-P1323
    [Leu31,Pro34]-Neuropeptide Y (human,rat)

    		Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    [Leu31,Pro34]-Neuropeptide Y(human,rat) is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) slao activates Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) can increase blood pressure in anesthetized rats and increases food intake .
    [Leu31,Pro34]-Neuropeptide Y (human,rat)
  • HY-121460
    Spiraprilat

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Spiraprilat is a potent angiotensin-converting enzyme (ACE) inhibitor. Spiraprilat has ability to improve left ventricular (LV) function and metabolism in anesthetized open-chest dogs with acute ventricular failure (ALVF) .
    Spiraprilat
  • HY-119291
    RA642

    		Phosphodiesterase (PDE) Others
    RA642 is a compound with vasodilatory and hypertensive effects, with the activity of increasing arterial blood pressure, enhancing cerebral blood flow, reducing cerebrovascular resistance and peripheral resistance, and having a papaverine-like relaxant effect on smooth muscle in anesthetized animals.
    RA642
  • HY-125673
    AC-178335

    		Somatostatin Receptor Neurological Disease
    AC-178335 is a SRIF antagonist, with a Ki of 172 nM. AC-178335 blocks SRIF inhibition of adenylate cyclase in vitro (IC50=5.1 μM). AC-178335 induces GH release in anesthetized rats .
    AC-178335
  • HY-N4209
    3α-Dihydrocadambine

    		Others Cardiovascular Disease
    3α-Dihydrocadambine is a natural product isolated from the heartwoods of Anthocephalus cadamba.3α-Dihydrocadambine exhibits dose-dependent hypotensive and anti-hypertensive effects in anesthetized normotensive rats and in conscious spontaneously hypertensive rats .
    3α-Dihydrocadambine
  • HY-19136
    WAY-100289

    		5-HT Receptor Neurological Disease
    WAY-100289 is an orally active antagonist for 5-HT3 receptor, that exhibits high affinity to the isolated rat vagus nerves with pA2 of 8.9. WAY-100289 inhibits the Bezold-Jarisch reflex in anesthetized and awake rats .
    WAY-100289
  • HY-19037
    SM-2470

    		Adrenergic Receptor Cardiovascular Disease Neurological Disease Metabolic Disease
    SM-2470 is a potent α1-adrenoceptor antagonist, has sympathetic nerve activity in anesthetized rats . SM-2470 is an antihypertensive agent. SM-2470 exhibits hypocholesterolaemic effect by the inhibition of cholesterol absorption related to the reduction of cholesterol solubilization .
    SM-2470
  • HY-105925
    Mefenidil

    MCN 2378

    		 Adrenergic Receptor Cardiovascular Disease
    Mefenidil (MCN 2378) is a selective cerebral vasodilator that is not affected by beta-adrenergic blockade. Mefenidil can be used in the study of cardiovascular disease. In monkey models, mefenidil preferentially increases cerebral blood flow over systemic (femoral) blood flow. Mefenidil is also able to reduce systemic arterial pressure in anesthetized dogs.
    Mefenidil
  • HY-17465
    Glycopyrrolate
    1 Publications Verification

    Glycopyrronium bromide; Glycopyrrolate bromide

    		 mAChR Cardiovascular Disease Neurological Disease Cancer
    Glycopyrrolate (Glycopyrronium bromide), a quaternary ammonium derivative, is a muscarinic receptor antagonist. Glycopyrrolate has bronchoprotective effect and produces a beneficial effect on blood pressure. Glycopyrrolate can be used for the research of bronchial diseases .
    Glycopyrrolate
  • HY-17465R
    Glycopyrrolate (Standard)

    		mAChR Neurological Disease Cancer
    Glycopyrrolate (Standard) is the analytical standard of Glycopyrrolate. This product is intended for research and analytical applications. Glycopyrrolate (Glycopyrronium bromide), a quaternary ammonium derivative, is a muscarinic receptor antagonist. Glycopyrrolate has bronchoprotective effect and produces a beneficial effect on blood pressure. Glycopyrrolate can be used for the research of bronchial diseases .
    Glycopyrrolate (Standard)
  • HY-129445
    SG-209

    		Potassium Channel Cardiovascular Disease
    SG-209 is a Nicorandil (HY-B0341) derivative that produces relaxation through potassium channel activation, while this action contributes to the vasodilating action of Nicorandil (HY-B0341) at higher concentrations. SG-209 dilates tracheal smooth muscle and increases tracheal blood flow in anesthetized dogs .
    SG-209
  • HY-102065
    SC-19220

    		Prostaglandin Receptor Others
    SC-19220 is a competitive prostaglandinn E2 receptor antagonist. SC-19220 increases the bladder capacity and reduced the voiding efficiency of micturition (elicited by slow transvesical filling) of urethane-anesthetized rats. SC-19220 can restores the balance in bone marrow granulocyte and monocyte production after burn sepsis .
    SC-19220
  • HY-129706
    LY127210 free base

    		Others Cardiovascular Disease
    LY127210 (free base) is a potent vasodilator with antihypertensive effects that reduces pressure in chloralose-anesthetized spontaneously hypertensive rats primarily by direct arteriolar dilation and to a lesser extent by decreasing cardiac output. LY127210 (free base) reduces blood pressure, heart rate and left ventricular end-diastolic pressure in hypertensive rats by reducing vascular resistance .
    LY127210 free base
  • HY-105090R
    Lerisetron (Standard)

    		5-HT Receptor Cardiovascular Disease Neurological Disease Cancer
    Lerisetron (Standard) is the analytical standard of Lerisetron. This product is intended for research and analytical applications. Lerisetron is a potent 5-HT3 antagonists and possess high-affinity binding for the 5-HT3 receptors with pKi value of 9.2. Lerisetron has a potent ability to inhibit the 5-HT-evoked reflex bradycardia in urethane-anesthetized rats[1].
    Lerisetron (Standard)
  • HY-119883
    A-61603 (free base）

    		Adrenergic Receptor Neurological Disease
    A-61603 free base is a potent adrenergic receptor agonist. A-61603 free base reduces carotid artery conductance in anesthetized pigs mediated by α1 and α2 adrenergic receptors (pEC50=7.25). A-61603 free base can be used as a probe to study adrenergic function .
    A-61603 (free base）
  • HY-129737
    A-62198

    		Endogenous Metabolite Cardiovascular Disease
    A-62198 is a potent and selective renin inhibitor with antihypertensive activity. A-62198 reduces mean arterial pressure (MAP) in anesthetized, salt-deprived monkeys in a dose-dependent manner. A-62198 induced MAP reduction in normal monkeys that reached statistical significance at the highest dose and significantly inhibited plasma renin activity (PRA) at all doses .
    A-62198
  • HY-118350
    FR 75513

    		Biochemical Assay Reagents Neurological Disease
    FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
    FR 75513
  • HY-118233
    Alilusem potassium

    M 17055

    		 Chloride Channel Neurological Disease
    Alilusem potassium is a diuretic. In anesthetized dogs undergoing water diuresis, Alilusem potassium effectively decreased free water clearance and increased Na+ and Cl- levels in excreted urine. When combined with Furosemide (HY-B0135) or Hydrochlorothiazid, Alilusem potassium further inhibited free water clearance. Alilusem potassium inhibited the lumen-positive transepithelial voltage and lumen-to-cistern Cl- flux in isolated rabbit cortical thick ascending limbs of Henle .
    Alilusem potassium
  • HY-108502
    KC 12291 hydrochloride

    		Sodium Channel Cardiovascular Disease
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na + current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo .
    KC 12291 hydrochloride
  • HY-107063
    AHR-1911

    10-Undecen-1-yl-thiopseudourea iodide

    		 Histamine Receptor Cancer
    AHR-1911 (10-Undecen-1-yl-Thiopseudourea Iodide;Isothiuronium) is a thiourea-based anti-inflammatory and anti-tumor agent that has an improving effect on burned skin. AHR-1911 produces histamine-like effects when injected intradermally and may reduce arterial pressure in anesthetized dogs. AHR-1911 inhibits tumor growth and reduces microsomal and C-polysome protein synthesis .
    AHR-1911
  • HY-118665
    L-736380

    		Cholecystokinin Receptor Metabolic Disease
    L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC50 values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED50, 1.7 mg/kg) .
    L-736380
  • HY-121670
    Ambenoxan

    		Others Neurological Disease
    Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan
  • HY-121670A
    Ambenoxan hydrochloride

    		Adrenergic Receptor Neurological Disease
    Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan hydrochloride
  • HY-106909A
    YM114

    KAE-393

    		 5-HT Receptor Cardiovascular Disease
    YM114 (KAE-393) is a highly potent and selective (5-HT)3-receptor antagonist that does not affect Veratridine (HY-N6691)- or electrical stimulation-induced bradycardia in anesthetized rats. YM114 inhibits 2-methyl-5-HT (HY-19358)-induced Bezold-Jarisch reflex, which originates from (5-HT)3-receptor located on the endings of vagal afferent nerves in the heart .
    YM114
  • HY-167848
    DMP-728 free base

    XL-118

    		 Others Cardiovascular Disease
    DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
    DMP-728 free base
  • HY-137055
    PF-3774076

    		Others Others
    PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
    PF-3774076

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: